Streetbeat News

NYXH

Nyxoah S.A.

https://www.nyxoah.com

Industry

Medical - Instruments & Supplies

Nyxoah S.A., a medical technology company, focuses on the development and commercialization of solutions to treat sleep disordered breathing conditions. It offers Genio system, a CE-Marked, patient-centric, and hypoglossal neurostimulation therapy to treat moderate to severe obstructive sleep apnea. The company was incorporated in 2009 and is headquartered in Mont-Saint-Guibert, Belgium.

Open

10.44

Mkt cap

365M

Volume

71K

High

10.63

P/E Ratio

-5.38

52-wk high

16.08

Low

10.35

Div yield

N/A

52-wk low

6.76

Nyxoah has announced the commercial launch of its Genio® innovative therapy in England, with the first patients being implanted at University College London Hospitals (UCLH).

Portfolio Pulse from

December 13, 2024 | 7:30 am

Nyxoah is set to participate in the Piper Sandler 36th Annual Healthcare Conference, which could provide the company with increased visibility and networking opportunities in the healthcare sector.

Portfolio Pulse from

November 20, 2024 | 9:15 pm

Nyxoah SA announced receiving a transparency notification from ResMed Inc. due to a passive crossing of a shareholding threshold, as per regulatory requirements.

Portfolio Pulse from

November 18, 2024 | 9:45 pm

Nyxoah S.A. (NYXH) held its Q3 2024 earnings call, discussing financial performance and company updates. Key participants included CEO Olivier Taelman and CFO Loic Moreau, with analysts from Piper Sandler, Stifel, Oppenheimer, Cantor Fitzgerald, and Baird attending.

Portfolio Pulse from

November 09, 2024 | 12:00 am

Nyxoah SA (NYXH) reported a Q3 loss of $0.68 per share, which was larger than the Zacks Consensus Estimate of a $0.46 loss. However, the company exceeded revenue expectations.

Portfolio Pulse from

November 07, 2024 | 1:30 am

Nyxoah SA has appointed John Landry as the new Chief Financial Officer, with the current CFO, Loïc Moreau, transitioning to President International. This move, along with the CEO's recent relocation to the U.S., highlights Nyxoah's strategic focus on the U.S. market.

Portfolio Pulse from

November 05, 2024 | 12:30 pm

HC Wainwright & Co. has maintained a Buy rating on Nyxoah (NASDAQ:NYXH) but lowered the price target from $18 to $17.

Portfolio Pulse from Benzinga Newsdesk

October 11, 2024 | 7:13 pm

Tesla's shares fell 5.6% in pre-market trading after a disappointing robotaxi unveiling event. Other stocks like A. O. Smith, Lilium, and Indivior also saw declines due to various reasons including lowered earnings forecasts and revenue guidance.

Portfolio Pulse from Avi Kapoor

October 11, 2024 | 12:40 pm

Nyxoah SA announced that BlackRock, Inc. holds a 3.25% stake in the company, consisting of 1,032,521 shares and 83,900 financial instruments, following a change in BlackRock's group structure.

Portfolio Pulse from Benzinga Newsdesk

October 09, 2024 | 8:32 pm

Nyxoah has raised $27 million through an at-the-market offering by selling 3 million shares. This move is likely to impact the company's stock price in the short term.

Portfolio Pulse from Benzinga Newsdesk

October 07, 2024 | 9:05 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.